Baudax Bio, Inc. (BXRX) Bundle
A Brief History of Baudax Bio, Inc. (BXRX)
Company Overview
Baudax Bio, Inc., established in 2018, focuses on the development and commercialization of innovative therapeutics for major unmet medical needs. The company is publicly traded under the ticker symbol BXRX.
Initial Public Offering (IPO)
Baudax Bio went public on October 16, 2019, raising approximately $15 million by offering 3.75 million shares at a price of $4.00 per share.
Key Product: ANJESO
ANJESO (meloxicam injection) is Baudax Bio’s lead product, approved by the FDA in December 2020 for the management of moderate to severe pain. It is a non-opioid analgesic designed for use in a hospital setting.
| Product | Approval Date | Indication | Formulation |
|---|---|---|---|
| ANJESO | December 2020 | Management of moderate to severe pain | Injection |
Financial Performance
As of Q2 2023, Baudax Bio reported revenues of approximately $1.2 million from product sales of ANJESO. The company had a net loss of around $2.5 million during the same period.
Funding and Financial Support
In August 2021, Baudax Bio completed a financing round that raised approximately $8.5 million through the sale of equity securities. This funding aimed to support product commercialization and general corporate purposes.
Stock Performance
As of October 2023, Baudax Bio's stock price was approximately $0.36. The company’s market capitalization was around $5.3 million.
Recent Developments
In September 2023, Baudax Bio announced a strategic restructuring plan intended to reduce operating expenses by approximately 30%. This plan includes workforce reductions and a consolidation of facilities.
Pipeline Products
Baudax Bio has a promising pipeline, including:
- BX1000: Investigational drug for postoperative pain management
- BX2000: New therapeutic candidate for cancer-related pain
| Pipeline Product | Indication | Status |
|---|---|---|
| BX1000 | Postoperative pain management | In Phase 2 clinical trials |
| BX2000 | Cancer-related pain | Pre-clinical stage |
Market Position and Competitors
Baudax Bio operates in the competitive pain management market, facing challenges from major players like Pfizer and Johnson & Johnson. The non-opioid analgesics market is projected to grow, potentially benefiting Baudax Bio’s positioning.
Management Team
The management team includes:
- Dr. Michael McGowan, CEO
- Mark E. Briner, CFO
- Kristin E. Williams, VP of Regulatory Affairs
Future Outlook
Baudax Bio aims to leverage its innovative product pipeline to capture market share in the pain management sector. Continuous evaluations of strategic partnerships and collaborations are expected to enhance growth opportunities moving forward.
A Who Owns Baudax Bio, Inc. (BXRX)
Overview of Ownership Structure
Baudax Bio, Inc. (BXRX) operates under a structure characterized by a mix of institutional and retail investors. As of the latest filings and reports, the ownership breakdown of the company illustrates a diverse base of stakeholders.
| Ownership Type | Percentage Owned | Number of Shares |
|---|---|---|
| Institutional Investors | 45% | 12,000,000 |
| Insider Ownership | 10% | 2,500,000 |
| Retail Investors | 45% | 12,000,000 |
Significant Institutional Shareholders
Baudax Bio's institutional ownership includes several key players in the financial sector. Below are some of the most prominent stakeholders:
| Institution | Shares Owned | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 3,500,000 | 13.5% |
| Vanguard Group, Inc. | 2,800,000 | 10.8% |
| UBS Asset Management | 1,200,000 | 4.6% |
Insider Ownership Breakdown
Insider ownership is a critical aspect of Baudax Bio’s governance. The following table provides a snapshot of individual insider shareholders.
| Insider Name | Position | Shares Owned |
|---|---|---|
| Robert E. Bult | CEO | 500,000 |
| John L. McMahon | CFO | 350,000 |
| Sarah J. Smith | COO | 300,000 |
Recent Market Performance
As of October 2023, Baudax Bio's stock performance has shown volatility, reflecting broader market trends and sector-specific factors. The latest closing price stood at $2.50 per share.
- Market Capitalization: $50 million
- 52-Week Range: $1.50 - $5.00
- Average Trading Volume: 1,200,000 shares
Public Float and Other Relevant Statistics
The public float is an essential indicator of the shares available for trading. The statistics below summarize the latest data related to Baudax Bio's share structure.
| Statistic | Value |
|---|---|
| Total Shares Outstanding | 30,000,000 |
| Public Float | 20,000,000 |
| Short Interest | 1,000,000 shares |
Baudax Bio, Inc. (BXRX) Mission Statement
Company Overview
Company Overview
Baudax Bio, Inc. (BXRX) is a biopharmaceutical company focused on innovative therapeutics for patients with significant unmet medical needs. The Company was founded in 2019 and is headquartered in Malvern, Pennsylvania. Baudax Bio aims to provide enhanced therapies through a strategic approach that includes drug development and commercialization.
Mission Statement
The mission of Baudax Bio is to improve patient outcomes by advancing innovative therapies that address critical therapeutic gaps in the medical field. The Company is dedicated to leveraging cutting-edge science and technology to develop novel treatments, particularly in the fields of analgesics and anesthesia.
Core Values
-
Innovation: Drive progress through scientific advancement.
-
Integrity: Uphold ethical principles in every action.
-
Collaboration: Foster partnerships to enhance therapeutic options.
-
Patient-Centric: Prioritize the needs and well-being of patients.
Strategic Focus Areas
-
Analgesic Therapeutics: Focus on innovative pain management solutions.
-
Anesthesia Products: Development of novel anesthesia agents.
-
Regulatory Strategy: Navigate FDA approval processes for quicker market access.
Financial Overview
- Innovation: Drive progress through scientific advancement.
- Integrity: Uphold ethical principles in every action.
- Collaboration: Foster partnerships to enhance therapeutic options.
- Patient-Centric: Prioritize the needs and well-being of patients.
Strategic Focus Areas
-
Analgesic Therapeutics: Focus on innovative pain management solutions.
-
Anesthesia Products: Development of novel anesthesia agents.
-
Regulatory Strategy: Navigate FDA approval processes for quicker market access.
Financial Overview
- Analgesic Therapeutics: Focus on innovative pain management solutions.
- Anesthesia Products: Development of novel anesthesia agents.
- Regulatory Strategy: Navigate FDA approval processes for quicker market access.
Financial Overview
As of Q2 2023, Baudax Bio reported the following financial metrics:
| Financial Metric | Q2 2023 Amount | Q1 2023 Amount | Change (%) |
|---|---|---|---|
| Revenue | $1.5 million | $1.2 million | 25% |
| Net Loss | ($6.3 million) | ($5.9 million) | 6.8% |
| Cash and Cash Equivalents | $20.1 million | $22.0 million | -8.64% |
| Total Assets | $25.3 million | $27.1 million | -6.6% |
| Total Liabilities | $12.5 million | $13.8 million | -9.42% |
Product Pipeline
Baudax Bio's product pipeline consists of several key programs:
| Product | Indication | Stage of Development | Expected Launch Year |
|---|---|---|---|
| Exparel | Post-operative pain | Marketed | 2017 |
| BXRX-001 | Acute pain | Phase 2 | 2024 |
| BXRX-002 | Chronic pain | Preclinical | 2026 |
Market Analysis
According to market research, the global analgesics market is expected to reach approximately $32 billion by 2026, growing at a CAGR of 4.5%. Baudax Bio operates in a competitive landscape that necessitates continued innovation and adaptation to market demands.
Conclusion
The mission statement of Baudax Bio reflects its commitment to enhancing healthcare through innovative therapeutic solutions. By focusing on patient needs and advancing its product pipeline, the Company aims to fulfill its aspiration of transforming patient care in the biopharmaceutical sector.
How Baudax Bio, Inc. (BXRX) Works
Company Overview
Company Overview
Baudax Bio, Inc., identified by its ticker symbol BXRX, is a clinical-stage pharmaceutical company. It specializes in the development of innovative therapeutics that address unmet medical needs in acute care settings. The company primarily focuses on the research and commercialization of novel medications.
Business Model
Baudax Bio operates on a model that integrates research and development with regulatory pathway navigation to bring therapies to market. The company's revenue streams include:
- Partnerships and collaborations
- Product sales upon regulatory approval
- Grants and government funding
Financial Performance
As of Q2 2023, Baudax Bio reported the following financial metrics:
| Financial Metric | Amount (in USD) |
|---|---|
| Revenue | $5.2 million |
| Net Income (Loss) | ($15.1 million) |
| Total Assets | $25.9 million |
| Total Liabilities | $10.4 million |
| Cash and Cash Equivalents | $15.2 million |
| Market Capitalization | $35 million |
Research and Development
The core of Baudax Bio’s operations lies in its research and development initiatives. The company’s pipeline includes:
- BX1000 for the management of pain
- BX2000 targeting sedation
- BX3000 in respiratory support therapy
As of 2023, the R&D expenditure was approximately $10 million.
Market Position
Baudax Bio positions itself within the acute care therapeutic market, which is projected to grow significantly. Key market statistics include:
| Market Segment | Projected Growth Rate (2023-2030) |
|---|---|
| Acute Pain Management | 5.8% |
| Sedation Management | 6.7% |
| Respiratory Support | 7.5% |
Regulatory Pathway
The company engages actively with the U.S. Food and Drug Administration (FDA) to ensure that its products meet the stringent regulatory requirements. Baudax Bio has submitted several Investigational New Drug (IND) applications:
- BX1000 - IND submitted in Q3 2022
- BX2000 - IND submitted in Q4 2022
- BX3000 - Under development with IND submission planned for 2024
Partnerships and Collaborations
Strategic partnerships are essential in accelerating drug development.
- Collaboration with PharmaCo for BX1000
- Partnership with MedTech for respiratory products
- Funding from BioHealth Grant for R&D
Recent Developments
In 2023, Baudax Bio announced:
- Completion of Phase 1 trials for BX1000
- FDA breakthrough designation for BX2000
- Acquisition of new lab facilities worth $3 million
Conclusion
Baudax Bio, Inc. continues to execute its strategy focused on innovative therapeutics, regulatory excellence, and strategic partnerships to enhance its offerings in the acute care sector.
How Baudax Bio, Inc. (BXRX) Makes Money
Revenue Generation Model
Revenue Generation Model
Baudax Bio, Inc. primarily generates revenue through the development and commercialization of pharmaceutical products, particularly in the area of pain management. The company's key product is Elyxyb, a formulation of dexmedetomidine, which has been developed for the acute treatment of migraine.
Product Portfolio
The following table outlines Baudax Bio's key products and their respective market strategies:
| Product | Indication | Market Status | Projected Annual Revenue |
|---|---|---|---|
| Elyxyb | Acute treatment of migraine | Commercialized | $10 million |
| Other Pipeline Products | Various indications | In development | Not yet determined |
Partnerships and Collaborations
Baudax Bio often engages in partnerships with other pharmaceutical companies to enhance its market reach and share resources. The following table illustrates some of its recent collaborations:
| Partner | Collaboration Type | Financial Terms | Purpose |
|---|---|---|---|
| Company A | Co-development | $5 million upfront, milestone payments | Expand product pipeline |
| Company B | Distribution Agreement | Revenue sharing | Market penetration |
Research and Development Investments
Investment in R&D is critical for Baudax Bio's growth. The recent financial data indicates the following expenditure:
| Year | R&D Expenditure | % of Total Revenue |
|---|---|---|
| 2020 | $7 million | 70% |
| 2021 | $6 million | 60% |
| 2022 | $5 million | 50% |
Market Challenges and Opportunities
Baudax Bio faces various challenges in the pharmaceutical market, which include competition and regulatory hurdles. However, opportunities exist in growing the pain management market:
- Market Size: The global pain management market is projected to reach $100 billion by 2025.
- Competitive Advantage: Unique formulation and effectiveness of Elyxyb.
- Regulatory Approval: Potential for FDA approval for additional indications.
Financial Performance
The financial performance of Baudax Bio can be summarized through the following metrics:
| Year | Total Revenue | Net Income | Operating Expenses |
|---|---|---|---|
| 2020 | $10 million | -$5 million | $15 million |
| 2021 | $12 million | -$4 million | $16 million |
| 2022 | $15 million | -$3 million | $18 million |
Baudax Bio, Inc. (BXRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support